Terms: = Pancreatic cancer AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Treatment
10 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
3. A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for Lung Adenocarcinoma.
Jin X; Hu Z; Sui Q; Zhao M; Liang J; Liao Z; Zheng Y; Wang H; Shi Y
J Immunol Res; 2022; 2022():6555810. PubMed ID: 35812244
[TBL] [Abstract] [Full Text] [Related]
4. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract] [Full Text] [Related]
5. Targeting the Stress-Induced Protein NUPR1 to Treat pancreatic Adenocarcinoma.
Santofimia-Castaño P; Xia Y; Peng L; Velázquez-Campoy A; Abián O; Lan W; Lomberk G; Urrutia R; Rizzuti B; Soubeyran P; Neira JL; Iovanna J
Cells; 2019 Nov; 8(11):. PubMed ID: 31744261
[TBL] [Abstract] [Full Text] [Related]
6. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct idh-Mutant Molecular Profiles.
Farshidfar F; Zheng S; Gingras MC; Newton Y; Shih J; Robertson AG; Hinoue T; Hoadley KA; Gibb EA; Roszik J; Covington KR; Wu CC; Shinbrot E; Stransky N; Hegde A; Yang JD; Reznik E; Sadeghi S; Pedamallu CS; Ojesina AI; Hess JM; Auman JT; Rhie SK; Bowlby R; Borad MJ; ; Zhu AX; Stuart JM; Sander C; Akbani R; Cherniack AD; Deshpande V; Mounajjed T; Foo WC; Torbenson MS; Kleiner DE; Laird PW; Wheeler DA; McRee AJ; Bathe OF; Andersen JB; Bardeesy N; Roberts LR; Kwong LN
Cell Rep; 2017 Mar; 18(11):2780-2794. PubMed ID: 28297679
[TBL] [Abstract] [Full Text] [Related]
7. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
Elhammali A; Ippolito JE; Collins L; Crowley J; Marasa J; Piwnica-Worms D
Cancer Discov; 2014 Jul; 4(7):828-39. PubMed ID: 24740997
[TBL] [Abstract] [Full Text] [Related]
8. Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
[TBL] [Abstract] [Full Text] [Related]
9. The CpG island methylator phenotype: what's in a name?
Hughes LA; Melotte V; de Schrijver J; de Maat M; Smit VT; Bovée JV; French PJ; van den Brandt PA; Schouten LJ; de Meyer T; van Criekinge W; Ahuja N; Herman JG; Weijenberg MP; van Engeland M
Cancer Res; 2013 Oct; 73(19):5858-68. PubMed ID: 23801749
[TBL] [Abstract] [Full Text] [Related]
10. Frequent mutation of isocitrate dehydrogenase (idh)1 and idh2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract] [Full Text] [Related]
